article thumbnail

Diabetes treatments are improving. Racial disparities are wider than ever

STAT

Despite advancements in insulin treatments over the past three decades, disparities in outcomes have widened among people with diabetes taking them, a new study found.

Diabetes 253
article thumbnail

Opinion: How I fought Big Pharma on insulin prices — and won

STAT

In 2013, I sat down at my computer and secured the URL t1international.com. I was only 25 years old, and I had already been living with type 1 diabetes for more than two decades. I wanted a place where I could collect and share everything I was learning about the global insulin price crisis.

Diabetes 325
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more

STAT

 Petrelintide is a once-weekly injection that is in Phase 2 studies and works on amylin, which has emerged as a key target for many drugmakers looking to go beyond GLP-1, the current widely prescribed type of medicine aimed at obesity and diabetes.

article thumbnail

UK children shorter, more obese and less healthy than 20 years ago

The Pharmacist

A steady decline in children’s health over the past two decades in the UK means they are now shorter and more likely to have obesity and type 2 diabetes.

Diabetes 124
article thumbnail

Lupin, Zydus sign licensing pact to co-market Saroglitazar Mg for chronic liver diseases in India

Express Pharma

Saroglitazar Mg was launched in India in September 2013 for the treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with type-2 diabetes not controlled by statins alone. It reduces co-morbidities (dyslipidemia, hypertriglyceridemia, and diabetes mellitus).

Diabetes 111
article thumbnail

Towards a new understanding of cardiovascular risk in diabetes

pharmaphorum

A new post-hoc analysis from Novo Nordisk of their SUSTAIN 6 and PIONEER 6 studies into semaglutide is looking to help ‘individualise’ treatment for diabetes patients by better predicting their cardiovascular lifetime risk. The two studies included 6,480 people with type 2 diabetes with high cardiovascular risk aged between 50-90 years.

article thumbnail

Large diabetic drug comparison study releases results

European Pharmaceutical Review

Results from the first study comparing four type 2 diabetes medications found that insulin glargine and liraglutide, two popular medications, performed best. If approved as a treatment, the findings give the diabetic population a more positive future, regarding management of their condition. Over 37 million Americans have diabetes.